IN2015DN00140A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00140A
IN2015DN00140A IN140DEN2015A IN2015DN00140A IN 2015DN00140 A IN2015DN00140 A IN 2015DN00140A IN 140DEN2015 A IN140DEN2015 A IN 140DEN2015A IN 2015DN00140 A IN2015DN00140 A IN 2015DN00140A
Authority
IN
India
Prior art keywords
species
immune library
antibody molecule
antigen
target antigen
Prior art date
Application number
Other languages
English (en)
Inventor
Haard Johannes Joseph Wilhelmus De
Christophe Frederic Jerome Blanchetot
Woning Sebastian Paul Van Der
Original Assignee
Argen X Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argen X Bv filed Critical Argen X Bv
Publication of IN2015DN00140A publication Critical patent/IN2015DN00140A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1055Protein x Protein interaction, e.g. two hybrid selection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN140DEN2015 2012-08-31 2013-08-30 IN2015DN00140A (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (1)

Publication Number Publication Date
IN2015DN00140A true IN2015DN00140A (https=) 2015-06-12

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
IN140DEN2015 IN2015DN00140A (https=) 2012-08-31 2013-08-30

Country Status (10)

Country Link
US (1) US20150203840A1 (https=)
EP (2) EP2890711B1 (https=)
JP (1) JP6391574B2 (https=)
CN (1) CN104583238A (https=)
AU (2) AU2013310924B2 (https=)
CA (1) CA2878712A1 (https=)
DK (1) DK2890711T3 (https=)
IL (1) IL236523B (https=)
IN (1) IN2015DN00140A (https=)
WO (1) WO2014033252A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ApoC3抗体およびその使用方法
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
WO2019118513A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2021241730A1 (ja) * 2020-05-29 2021-12-02 第一三共株式会社 炎症性腸疾患に対する治療用抗体
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
EP4615493A1 (en) 2022-11-08 2025-09-17 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375931T3 (es) * 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
CN1845937A (zh) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 抗il-20抗体和结合伴侣以及在炎症中的使用方法
EP1606316A2 (en) * 2003-03-24 2005-12-21 ZymoGenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
DK1899378T3 (da) * 2005-06-21 2010-02-01 Xoma Technology Ltd IL-1 beta-bindende antistoffer og fragmenter deraf
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-22(il-22)之抗體及其用途
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
JP6033229B2 (ja) * 2010-11-24 2016-11-30 レクシコン ファーマシューティカルズ インコーポレイテッド Notumペクチンアセチルエステラーゼと結合する抗体

Also Published As

Publication number Publication date
AU2017204188A1 (en) 2017-07-13
US20150203840A1 (en) 2015-07-23
EP2890711B1 (en) 2017-01-04
IL236523A0 (en) 2015-02-26
EP2977386A1 (en) 2016-01-27
IL236523B (en) 2018-12-31
DK2890711T3 (en) 2017-02-27
CA2878712A1 (en) 2014-03-06
AU2013310924B2 (en) 2017-08-03
JP6391574B2 (ja) 2018-09-26
CN104583238A (zh) 2015-04-29
EP2890711A1 (en) 2015-07-08
WO2014033252A1 (en) 2014-03-06
AU2013310924A1 (en) 2015-01-29
AU2013310924A8 (en) 2015-04-30
JP2015530087A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
IN2015DN00140A (https=)
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
MX353278B (es) Raton con cadena ligera comun.
TN2014000120A1 (en) Cd27l antigen binding proteins
WO2013188693A8 (en) Antigen binding constructs to cd3
MX372821B (es) Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos.
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
MX370651B (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización.
CR20130128A (es) Nuevas proteínas de unión a antígenos
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201791393A2 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
MX2014014804A (es) Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201691321A1 (ru) Антитела и способы их применения
GT201400045A (es) Anticuerpo anti-abtcr
EA201592285A1 (ru) Антигенсвязывающие белки к рецептору онкостатина м
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
EP2671976A4 (en) ANTIBODY MANUFACTURING METHOD, ANTIBODY AND ANTIBODY LIBRARY OBTAINED THEREFROM
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
MX2015005757A (es) Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
EA201390537A1 (ru) Антигенсвязывающие белки, связывающиеся с онкостатином м (osm)